


Journal Pre-proof

Minimally interface vitrectomy for rhegmatogenous retinal detachment with a single break in young patients

Marco Mura, Leonore Engelbrecht, Marc D. de Smet, Patrik Schatz, Danilo Iannetta, Valmore A. Semidey, J. Fernando Arevalo



PII: S2451-9936(20)30091-8

DOI: <https://doi.org/10.1016/j.ajoc.2020.100739>

Reference: AJOC 100739

To appear in: *American Journal of Ophthalmology Case Reports*

Received Date: 11 November 2019

Revised Date: 29 April 2020

Accepted Date: 6 May 2020

Please cite this article as: M. Mura, L. Engelbrecht, M.D. de Smet, P. Schatz, D. Iannetta, V.A. Semidey, J.F. Arevalo, Minimally interface vitrectomy for rhegmatogenous retinal detachment with a single break in young patients, *American Journal of Ophthalmology Case Reports* (2020), doi: <https://doi.org/10.1016/j.ajoc.2020.100739>.

This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

© 2020 Published by Elsevier Inc.

Minimally Interface Vitrectomy for Rhegmatogenous Retinal Detachment with a Single Break in Young Patients

Marco Mura MD^{1,2}, Leonore Engelbrecht MD¹, Marc D. de Smet MD PhD³, Patrik Schatz MD¹, Danilo Iannetta MD⁴, Valmore A. Semidey MD¹, J. Fernando Arevalo MD PhD⁵

¹King Khaled Eye Specialist Hospital, Riyadh, Kingdom of Saudi Arabia

²University of Illinois, Chicago, USA

³Microinvasive Ocular Surgery Center, Lausanne, Switzerland

⁴Royal Liverpool University Hospital, St. Paul's Eye Unit, Liverpool, United Kingdom

⁵Wilmer Eye Institute, Johns Hopkins University, Baltimore, MD, USA

Corresponding author:

Marco Mura, MD

King Khaled Eye Specialist Hospital

P.O. Box 7191, Riyadh, Kingdom of Saudi Arabia, 11462

Tel: +966509259160

Fax: +966114821234 extension 2656

Email: drmmura@yahoo.com

Abstract

Purpose: This study evaluates a new surgical technique consisting of minimal vitreous removal under air (minimal interface vitrectomy; MIV) to reduce postoperative complications while preserving the ability to address surgical factors at the retinal break.

Methods: This retrospective analysis examined the outcomes of minimal interface vitrectomies in consecutive cases, with a minimum 12-month follow-up period, of primary rhegmatogenous retinal detachment (RRD), recurrent RRD after pars plana vitrectomy (PPV), or failed surgery after primary scleral buckling surgery (SBS).

Results: Twelve eyes of 12 patients with RRD underwent MIV. The total surgical duration was 190-300 seconds (mean, 245.25 seconds). Eight (66.7%) eyes were treated with cryotherapy, and 4 (33.3%) with endolaser to seal the retinal break. Successful, complete retinal reattachment was achieved in all eyes and maintained during follow-up. No intra- or postoperative complications occurred and no patients developed inflammation or cataract during follow-up.

Conclusion and Importance: We effectively removed traction and subretinal fluid and treated breaks with endolaser or cryotherapy by using a novel minimal interface vitrectomy technique in this selected population.

Key words: minimal interface vitrectomy, rhegmatogenous retinal detachment, laser retinopexy

INTRODUCTION

Rhegmatogenous retinal detachment (RRD) is a sight-threatening disease that occurs in 0.1% to 1.0% of eyes after cataract surgery, and in 1 in 10,000 people per year in the general population.^{1,2} Pneumatic retinopexy (PR), scleral buckling surgery (SBS), and primary pars plana vitrectomy (PPV) with or without scleral buckling are traditional vitreoretinal surgery techniques used to repair RRD.

Pneumatic retinopexy was first described in 1986.³ It was rapidly adopted because it enabled in-office surgery. However, due to an inability to address possible traction at the site of the break and the risk of gas-induced formation of distant new breaks in a non-vitrectomized eye,⁴ reattachment rate after a single surgery has been reported to be lower and recurrence rate is higher, compared with treatment with SBS or PPV.⁵ Scleral buckling has been employed to repair RRD for over 70 years, but a primary disadvantage of SBS is the possibility of inducing high refractive errors.

Since the advent of new microsurgical instruments, wide-angle viewing systems, and heavy liquids, there has been a trend away from the use of SBS in favor of PPV. After its introduction in 2002, small-gauge transconjunctival vitrectomy was rapidly adopted and has become the gold standard in vitreoretinal surgery.^{6,7}

Successively, limited core and peripheral vitreous removal to treat primary RRD have been advocated.⁸ A complete vitrectomy has been shown to increase oxygen levels in the vitreous cavity and cause cataract progression.⁹ The advantage of limited vitrectomy may include a reduction of cataract formation and a decreased inflammatory response. The latter may reduce the risk of proliferative vitreoretinopathy (PVR).

The purpose of this study was to evaluate the results of a novel surgical technique consisting of minimal vitreous removal under air (minimal interface vitrectomy; MIV); it can be used to reduce postoperative complications (such as inflammatory response, re-detachment and cataract) associated to traditional vitreoretinal surgery, while preserving the option to address surgical factors, such as traction at the break.

MATERIALS AND METHODS

This study was a retrospective analysis of outcomes of MIV in a consecutive series of cases of primary RRD, recurrent RRD after PPV, or failed surgery after primary SBS. All patients were phakic and had a single retinal break. The inclusion criterion included a minimum post-surgical follow-up period of 12 months.

None of the patients who underwent MIV had signs of Grade B or greater proliferative vitreo-retinopathy (PVR) or anterior segment optical opacity that precluded adequate visualization of the posterior segment. The posterior vitreous was evaluated pre- and postoperatively.

Twelve eyes of 12 patients (7 males and 5 females) had MIV surgery; all surgical procedures were performed with the 25- or 27-gauge vitrectomy system.

The principles of the Declaration of Helsinki and good clinical practice guidelines were followed. The Institutional Review Board (IRB) of KKESH approved the study. The following data were obtained from the patients' charts: age, gender, laterality, extent of

detachment, previous surgery, type of tamponade agent, postoperative intraocular pressure (IOP), head positioning, total surgical time, type of retinopexy (cryotherapy or endolaser), postoperative lens status, and anatomical outcome. The mean patient's age was 26 years (range, 8-38 years). Seven eyes (53%) had 2 detached superior retinal quadrants, 3 (25%) had 3 involved quadrants, and 2 (16.6%) had total retinal detachment. The retinal tear was located superiorly between 10 o'clock and 2 o'clock, temporally near the horizontal midline. Ten patients were myopic and 2 had a history of prior ocular trauma. Three patients had lattice degeneration and were treated intraoperatively with endolaser. Three (25%) eyes had a history of prior failed encircling SBS, and 2 (16.6%) had undergone previous LASIK for myopic correction. Patient characteristics are reported in Table 1.

Pediatric surgeries were performed under general anesthesia. All other surgical procedures were performed under local anesthesia administered by a sub-Tenon's injection or peribulbar infiltration. Additional local anesthesia was administered in the operative field if necessary, and at the end of surgery to pediatric patients for postoperative analgesia. All surgical procedures were performed using 27 or 25-gauge sutureless vitrectomy system (Alcon, Fort Worth, TX, USA).

The surgical approach consisted of first displacing the conjunctiva immediately above the designated sclerotomy site to avoid communication between the two entry sites. Next, a transconjunctival cannula was inserted diagonally through the sclera, 3.5 mm from the limbus, using a beveled trocar to create a conjunctival and scleral incision. Three cannulas were placed in the inferotemporal, supero-temporal, and supero-nasal quadrants. In some cases, an anterior location of the break required the use of a chandelier light in the inferonasal quadrant to facilitate surgical maneuvers under scleral depression. A BIOM (Oculus Optikgeräte GmbH, Wetzlar, Germany) viewing system was used for posterior visualization. The Constellation® Vision System platform (Alcon, Fort Worth, TX, USA) was primed and the infusion line was switched to 35 mmHg continuous air infusion. No BSS was infused in the vitreous cavity in all cases. A limited sectorial vitrectomy around the break was performed to release all significant tangential and antero-posterior tractional forces while draining the subretinal fluid through the break (figure 1,2). After the subretinal fluid was removed, the cutter was brought to the center of the vitreous cavity and advanced posteriorly while cutting, to create space for air to fill the eye and allow a reasonable tamponade (figure 3,4). In cases where posterior vitreous cortex remained attached, no surgical detachment was performed. Endolaser or cryotherapy was then applied to the break (figure 5). The choice of laser, cryopexy, and type of tamponade agent varied according to the detachment characteristics. Patients with a retinal tear in the superior quadrants (from 9 to 3 o'clock) or a break ≤ 1.5 clock-hours were treated with cryopexy or endolaser and an air bubble. Cases of inferior detachments or a break > 1.5 clock-hours were treated with laser and sulfur hexafluoride (SF₆) 20%. All patients were asked to maintain a specific head position, dependent on the location of the break, for a period of 5 days after surgery. The key steps of MIV are highlighted in the accompanying video (video 1).

RESULTS

Twelve eyes of 12 patients (7 males and 5 females) with various types of primary RRD underwent MIV. Eight detachments were operated by using the 27-gauge vitrectomy system (66.7%); the other 4 were operated with the 25-gauge system (33.3%) based on availability of the instrumentation. The total surgical time varied from 190 to 300 seconds (mean, 245.25 seconds); there was no significant difference in the duration of the intervention between the two vitrectomy systems. Three eyes in our population had a pre-existent posterior vitreous detachment based on the presence of a Weiss ring. Eight (66.7%) eyes were treated with cryoretinopexy and 4 (33.3%) were treated with endolaser. Six eyes received air tamponade; the other 6 received an SF₆ 20% tamponade.

The average postoperative IOP was 12.75 mmHg (5-18 mmHg). According to the location of the retinal break, patients were required to maintain a specific head position for 5 days; all patients were allowed to discontinue their position for a maximum of 10 minutes per hour. Successful complete retinal reattachment was achieved and maintained throughout follow-up in all 12 eyes, with a mean follow-up of 15 months (12-21 months). All patients were phakic at the time of surgery; none developed cataracts during follow-up.

DISCUSSION

Our study describes a new surgical technique, namely minimal interface vitrectomy (MIV), which effectively removed traction and subretinal fluid and treated breaks with endolaser or cryoretinopexy successfully in 12 cases.

RRD is caused by dynamic forces in the vitreous cavity, in addition to vitreous syneresis. The dynamic forces created by eye movement allow liquid gel shift and the formation of intraocular currents. At the location where the vitreous is most firmly attached to the retina, these currents can cause a tear and push fluid into the subretinal space. These strong vitreoretinal attachments can also sustain traction and cause the retinal break to remain open. Finally, retinal detachment occurs when the amount of subretinal fluid overwhelms the drainage capacity of the retinal pigment epithelium (RPE) pump.

One of the options to repair RRD is pneumatic retinopexy. However, complications in pneumatic retinopexy occur when the stretching of the vitreous from the growing gas bubble and the limited space in the vitreous cavity create or increase traction in other areas of the retina. Some reports state that 7–22% of new breaks occur after pneumatic retinopexy^{4,8-10,12} and the formation of macular holes has also been described.¹³ Fluid resorption can be delayed if head positioning is not adequate. Bullous retinal detachments or large retinal breaks could cause the migration of gas or “fish egg bubbles” into the subretinal space.¹⁴ In pneumatic retinopexy, excessive subretinal fluid or loss of direct visualization of the break in the gas interface avoids complete intraoperative treatment of the retinal break, and leads to additional laser treatment during the postoperative period.

Another treatment option, scleral buckle neutralizes, but does not eliminate, the tractional component.¹⁵ In some studies, scleral buckles have a re-detachment rate of

up to 47% in the first year.¹⁶ Most failures are caused by parallax errors when determining proper buckle placement with consequent unsupported breaks. For inexperienced surgeons or in highly myopic eyes, the possibility of perforation of the sclera and choroid with sutures is high, resulting in subretinal bleeding or endophthalmitis. Strabismus after scleral buckling has been reported in 5–25% of cases.¹⁷ Post-operative refractive errors of up to -2.5 diopters, an increase of 0.99 mm in axial length, and significantly reduced anterior chamber depth have also been described.^{18,19} Another study clarified that circumferential SBS produced prolonged irregular and asymmetric corneal shape alterations.²⁰ Recently, a significant change of higher order aberrations after SBS was also reported.²¹

MIV has several advantages compared to traditional pneumatic retinopexy and SBS. In our newly described technique (MIV), we remove a limited amount of vitreous under air, achieving rapid and precise removal of the vitreal traction surrounding the retinal break. Simultaneously, we create a space for the air to expand, which avoids secondary traction on other areas of the retina. Furthermore, we drain most subretinal fluid without the need for an intraoperative posterior sclerotomy. Continuous infusion of air via the inferotemporal line allows us to work under a single large air bubble in the vitreous cavity, avoiding small bubble migration under the retina. Intraoperative subretinal fluid drainage makes postoperative head positioning less critical. In addition, retinopexy with laser or cryotherapy can be performed during the surgery, with consequent faster chorioretinal adhesion formation, more rapid recovery time, and no requirement for further in-office treatment when the bubble disappears.

This technique is a rapid procedure, using small incisions and minimal manipulation that does not generate a significant inflammatory response. In our study, the day after surgery, eyes did not show any intraocular inflammation (no cells or trace cells). Previous studies have demonstrated a significant increase in the intraocular level of inflammatory cytokines (Monocyte chemoattractant protein-1 [MCP-1], interleukin [IL]-6, and IL-8), which are triggered by surgical trauma. Cytokines can cause stimulation and migration of macrophages, RPE cells, glial cells, and fibroblastic cells into the vitreous, where they form extracellular matrix proteins and organize into membranes.²²⁻²⁴ These proliferative membranes attach to the retina and eventually contract, causing failure of a surgically repaired detachment.²⁵ Hypothetically, maintaining an attached posterior hyaloid (as in our patient population) could serve as a scaffold for growth of the membranes and create retinal contraction. However, the minimal traumatic approach in MIV, combined with small gauge instruments and subsequent absence of an inflammatory response, could explain why no PVR developed in any of our patients during follow-up; this was essential for good outcomes in our patient population.

Furthermore, limited vitreous removal with preservation of posterior and anterior cortex can offer the advantage of reducing cataract formation, compared to patients undergoing full vitrectomy. In our patient population, refractive errors and opacification of the lens were not observed throughout follow-up. Due to the use of air or gas tamponades, intraocular currents were neutralized, allowing effective retinopexy after the application of laser therapy or cryotherapy. Furthermore, with this technique, all cases of primary retinal detachment and recurrence due to failed buckling procedures were effectively treated. We advocate the use of MIV in phakic patients with a single break, without PVR. This new technique could be helpful for post-surface corneal

ablation patients who have high(er) expectations of maintaining their previous refractive enhancement. The limitations of this study included its retrospective study design, small number of patients, and lack of a control group.

CONCLUSIONS

To conclude, using MIV in a population of young patients with RRD and a single break a population of young patients with RRD and a single break,, we could effectively remove traction and subretinal fluid, properly treat the break with endolaser or cryotherapy, and facilitate rapid retinal reattachment in all study eyes. This minimally invasive technique also reduce the inflammatory response and could reduce the risk of PVR compared to more invasive surgery. Further prospective studies are necessary to define the role of this new technique. For example, it needs to be demonstrated if the technique could be ideal for the typical older patient who present to us with a PVD and has a superior break. This technique would basically then be considered as an alternative to pneumatic retinopexy or retinopexy “plus” kind of procedure.

Acknowledgments and Disclosures

Funding: No funding or grant support

Conflict of Interest: The authors have no financial disclosures.

Authorship: All authors attest that they meet the current ICMJE criteria for Authorship

Patient Consent: This report does not contain any personal identifying information.

Acknowledgment: None

Journal Pre-proof

REFERENCES

1. Haimann MH, Burton TC, Brown CK. Epidemiology of retinal detachment. *Arch Ophthalmol*. 1982; 100:289–292. <https://doi.org/10.1001/archophth.1982.01030030291012>
2. Van de Put MAJ, Hooymans JMM, Los LI, Dutch Rhegmatogenous Retinal Detachment Study Group. The incidence of rhegmatogenous retinal detachment in The Netherlands. *Ophthalmology*. 2013; 120:616–622. <https://doi.org/10.1016/j.ophtha.2012.09.001>
3. Hilton GF, Grizzard WS. Pneumatic retinopexy. A two-step outpatient operation without conjunctival incision. *Ophthalmology*. 1986; 93:626–641. [https://doi.org/10.1016/s0161-6420\(86\)33696-0](https://doi.org/10.1016/s0161-6420(86)33696-0)
4. Grizzard WS, Hilton GF, Hammer ME, Taren D, Brinton DA. Pneumatic retinopexy failures. Cause, prevention, timing, and management. *Ophthalmology*. 1995; 102:929–936. [https://doi.org/10.1016/s0161-6420\(95\)30932-3](https://doi.org/10.1016/s0161-6420(95)30932-3)
5. Hatfeg E, Sena DF, Fallano KA, Crews J, Do DV. Pneumatic retinopexy versus scleral buckle for repairing simple rhegmatogenous retinal detachments. *Cochrane Database Syst Rev*. 2015; 5:CD008350. <https://doi.org/10.1002/14651858.cd008350.pub2>
6. Fujii GY, De Juan E Jr, Humayun MS, et al. Initial experience using the transconjunctival sutureless vitrectomy system for vitreoretinal surgery. *Ophthalmology*. 2002; 109:1814–1820. [https://doi.org/10.1016/s0161-6420\(02\)01119-3](https://doi.org/10.1016/s0161-6420(02)01119-3)
7. Fujii GY, De Juan E Jr, Humayun MS, et al. A new 25-gauge instrument system for transconjunctival sutureless vitrectomy surgery. *Ophthalmology*. 2002; 109:1807–1812; discussion 1813. [https://doi.org/10.1016/S0161-6420\(02\)01179-X](https://doi.org/10.1016/S0161-6420(02)01179-X)
8. Mura M, Tan SH, De Smet MD. Use of 25-gauge vitrectomy in the management of primary rhegmatogenous retinal detachment. *Retina*. 2009; 29:1299–1304. <https://doi.org/10.1097/iae.0b013e3181aa0f5f>
9. Hokekamp NM, Bai F, Shui YB, Almony A, Beebe DC. Ischemic diabetic retinopathy may protect against nuclear sclerotic cataract. *Am J Ophthalmol* 2010 Oct; 150(4):543-5505
10. Tornambe PE, Hilton G.F Pneumatic retinopexy. A multicenter randomized controlled clinical trial comparing pneumatic retinopexy with scleral buckling. The Retinal Detachment Study Group. *Ophthalmology*. 1989; 96:772–784. [https://doi.org/10.1016/S0161-6420\(89\)32820-X](https://doi.org/10.1016/S0161-6420(89)32820-X)
11. Chen JC, Robertson JE, Coonan P, et al. Results and complications of pneumatic retinopexy. *Ophthalmology*. 1988; 95:601–608. [https://doi.org/10.1016/S0161-6420\(88\)33134-9](https://doi.org/10.1016/S0161-6420(88)33134-9)
12. Poliner LS, Grand MG, Schoch LH, et al. New retinal detachment after pneumatic retinopexy. *Ophthalmology*. 1987; 94:315–318. [https://doi.org/10.1016/S0161-6420\(87\)33445-1](https://doi.org/10.1016/S0161-6420(87)33445-1)
13. Proulx AA, Sheidow TG. Development of macular hole in the early postoperative period following pneumatic retinopexy. *Ophthalmic Surg Lasers Imaging*. 2006; 37:481–483. <https://doi.org/10.3928/15428877-2006-11>

14. Hilton GF, Tornambe PE. Pneumatic retinopexy. An analysis of intraoperative and postoperative complications. The Retinal Detachment Study Group. *Retina*. 1991; 11:285–294. <https://doi.org/10.1097/00006982-199111030-00003>
15. Smiddy WE, Glaser BM, Michels RG, de Bustros S. Scleral buckle revision to treat recurrent rhegmatogenous retinal detachment. *Ophthalmic Surg*. 1990; 21:716–720. <https://doi.org/10.3928/1542-8877-19901001-11>
16. Heimann H, Bartz-Schmidt KU, Bornfeld N, et al. Scleral buckling versus primary vitrectomy in rhegmatogenous retinal detachment: a prospective randomized multicenter clinical study. *Ophthalmology*. 2007; 114:2142–2154. <https://doi.org/10.1016/j.ophtha.2007.09.013>
17. Seaber JH, Buckley EG. Strabismus after retinal detachment surgery: etiology, diagnosis, and treatment. *Semin Ophthalmol*. 1995; 10:61–73. <https://doi.org/10.3109/08820539509059981>
18. Smiddy WE, Loupe DN, Michels RG, Enger C, Glaser BM, deBustros S. Refractive changes after scleral buckling surgery. *Arch Ophthalmol*. 1989; 107:1469–1471. <https://doi.org/10.1001/archopht.1989.01070020543036>
19. Goezinne F, La Heij EC, Berendschot TT, et al. Anterior chamber depth is significantly decreased after scleral buckling surgery. *Ophthalmology*. 2010; 117:79–85. <https://doi.org/10.1016/j.ophtha.2009.06.052>
20. Hayashi H, Hayashi K, Nakao F, Hayashi F. Corneal shape changes after scleral buckling surgery. *Ophthalmology*. 1997; 104:831–837. [https://doi.org/10.1016/s0161-6420\(97\)30226-7](https://doi.org/10.1016/s0161-6420(97)30226-7)
21. Okamoto F, Yamane N, Okamoto C, Hiraoka T, Oshika T. Changes in higher-order aberrations after scleral buckling surgery for rhegmatogenous retinal detachment. *Ophthalmology*. 2008; 115:1216–1221. <https://doi.org/10.1016/j.ophtha.2007.09.016>
22. Yoshida S, Kobayashi Y, Nakao S, et al. Differential association of elevated inflammatory cytokines with postoperative fibrous proliferation and neovascularization after unsuccessful vitrectomy in eyes with proliferative diabetic retinopathy. *Clin Ophthalmol*. 2017; 11:1697–1705. <https://doi.org/10.2147/opth.s141821>
23. Newsome DA, Rodrigues MM, Machemer R. Human massive periretinal proliferation. In vitro characteristics of cellular components. *Arch Ophthalmol*. 1981 99:873–880. <https://doi.org/10.1001/archopht.1981.03930010873017>
24. Yoshida A, Elner SG, Bian Z, Elner V. Induction of interleukin-8 in human retinal pigment epithelial cells after denuding injury. *Br J Ophthalmol*. 2001; 85:872–876. <https://doi.org/10.1136/bjo.85.7.872>
25. Ricker LJ, Kijlstra A, de Jager W, Liem AT, Hendrikse F, La Heij EC. Chemokine Levels in Subretinal Fluid Obtained during Scleral Buckling Surgery after Rhegmatogenous Retinal Detachment. *Invest Ophthalmol Vis Sci*. 2010; 51:4143–4150. <https://doi.org/10.1167/iovs.09-5057>

TABLES

Patient No.	Age	Gender	Eye Involved	No. of Quadrants Involved	Location of Tear	Previous Surgery
1	34	Male	Right	2	Superior	None
2	12	Male	Right	3	Superior	Scleral Buckle
3	29	Female	Left	4	Temporal	LASIK
4	35	Male	Left	3	Superior	LASIK
5	20	Female	Right	3	Superior	Scleral Buckle
6	38	Male	Left	2	Temporal	None
7	8	Male	Left	3	Superior	None
8	32	Female	Right	4	Superior	None
9	35	Female	Right	2	Superior	None
10	28	Male	Left	2	Inferior	None
11	30	Male	Right	2	Inferior	Scleral Buckle
12	16	Female	Left	2	Superior	None

Table 1. Demographic and preoperative characteristics of patients before MIV*

*MIV= Minimal Interface Vitrectomy; LASIK= Laser-assisted in-situ keratomileusis; No.= Number.

FIGURE CAPTIONS


Figure 1. **Limited interface vitrectomy under air infusion (cutter-on).** The subretinal fluid is aspirated with 25 gauge vitreous cutter in cutter-on modality until the local traction is released in a case of supero-temporal rhegmatogenous retinal detachment macula off.

Figure 2. **Subretinal fluid aspiration.** The residual subretinal fluid is removed with 25 gauge vitreous cutter (cutter-off) when no more traction is present.


Figure 3. **Limited core interface vitrectomy.** After total retinal reattachment under air the vitreous cutter can be advanced slowly towards the optic disc in cutting mode to create uniform space for the air/gas bubble.

Figure 4. **Retinal reattachment under air fill.** The retina is reattached under air. At this stage laser/cryopexy can be applied.


Figure 5. **Retinopexy.** Cryotherapy under air of supero-temporal break.




Journal Pre-proof




Journal



Journal



Journal



Author declaration

[Instructions: Please check all applicable boxes and provide additional information as requested.]

1. Conflict of Interest

Potential conflict of interest exists:

We wish to draw the attention of the Editor to the following facts, which may be considered as potential conflicts of interest, and to significant financial contributions to this work:

The nature of potential conflict of interest is described below:

No conflict of interest exists.

We wish to confirm that there are no known conflicts of interest associated with this publication and there has been no significant financial support for this work that could have influenced its outcome.

2. Funding

Funding was received for this work.

All of the sources of funding for the work described in this publication are acknowledged below:

[List funding sources and their role in study design, data analysis, and result interpretation]

No funding was received for this work.

3. Intellectual Property

We confirm that we have given due consideration to the protection of intellectual property associated with this work and that there are no impediments to publication, including the timing of publication, with respect to intellectual property. In so doing we confirm that we have followed the regulations of our institutions concerning intellectual property.

4. Research Ethics

We further confirm that any aspect of the work covered in this manuscript that has involved human patients has been conducted with the ethical approval of all relevant bodies and that such approvals are acknowledged within the manuscript.

IRB approval was obtained (required for studies and series of 3 or more cases)

Written consent to publish potentially identifying information, such as details or the case and photographs, was obtained from the patient(s) or their legal guardian(s).

5. Authorship

The International Committee of Medical Journal Editors (ICMJE) recommends that authorship be based on the following four criteria:

1. Substantial contributions to the conception or design of the work; or the acquisition, analysis, or interpretation of data for the work; AND
2. Drafting the work or revising it critically for important intellectual content; AND
3. Final approval of the version to be published; AND
4. Agreement to be accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. For more information on authorship, please see <http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-authors-and-contributors.html#two>.

All listed authors meet the ICMJE criteria. We attest that all authors contributed significantly to the creation of this manuscript, each having fulfilled criteria as established by the ICMJE.

One or more listed authors do(es) not meet the ICMJE criteria.

We believe these individuals should be listed as authors because:

[Please elaborate below]

We confirm that the manuscript has been read and approved by all named authors.

We confirm that the order of authors listed in the manuscript has been approved by all named authors.

6. Contact with the Editorial Office

The Corresponding Author declared on the title page of the manuscript is:

[Marco Mura]

This author submitted this manuscript using his/her account in EVISE.

We understand that this Corresponding Author is the sole contact for the Editorial process (including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors about progress, submissions of revisions and final approval of proofs.

We confirm that the email address shown below is accessible by the Corresponding Author, is the address to which Corresponding Author's EVISE account is linked, and has been configured to accept email from the editorial office of American Journal of Ophthalmology Case Reports:

[Insert email address you wish to use for communication with the journal here]



Someone other than the Corresponding Author declared above submitted this manuscript from his/her account in EVISE:

[Insert name below]

We understand that this author is the sole contact for the Editorial process

(including EVISE and direct communications with the office). He/she is responsible for communicating with the other authors, including the Corresponding Author, about progress, submissions of revisions and final approval of proofs.

We the undersigned agree with all of the above.

Author's name (Fist, Last)	Signature	Date
1. <u>MARCO MURA</u>		<u>31 Oct 2019</u>
2. <u>VALMORE SEMIDEY</u>		<u>31 Oct 2019</u>
3. <u>LEONORE ENGELBRECHT</u>	<u>Leonore Engelbrecht</u>	<u>6 Nov 2019</u>
4. <u>DANILO IANETTA</u>	<u>Daniilo Ianetta</u>	<u>4 Nov 2019</u>
5. <u>MARC DE SMET</u>	<u>Marc de Smet</u>	<u>Nov 3, 2019</u>
6. <u>J FERNANDO AREVALO</u>	<u>JF Arevalo</u>	<u>11-3-19</u>
7. _____	_____	_____
8. _____	_____	_____
9. _____	_____	_____
10. _____	_____	_____